Page last updated: 2024-12-08

digitoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
DigitalisgenusA genus of toxic herbaceous Eurasian plants of the Plantaginaceae which yield cardiotonic DIGITALIS GLYCOSIDES. The most useful species are Digitalis lanata and D. purpurea.[MeSH]PlantaginaceaeA plant family of order Lamiales. The Plantago genus is best known. Lesser known members include Hippuris, Littorella and Callitriche.[MeSH]

Cross-References

ID SourceID
PubMed CID441207
CHEMBL ID254219
CHEBI ID28544
SCHEMBL ID20940
MeSH IDM0006383

Synonyms (159)

Synonym
glucodigin
cristapurat
digitoksin
crystodigin
lanatoxin
digitophyllin
unidigin
carditoxin
nsc-7529
cardidigin
cardigin
purpurid
MLS000069787 ,
smr000058529
ACON0_000319
(3beta,5beta)-3-{[2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide
tri-digitoxoside [german]
mono-glycocard
card-20(22)-enolide, 3-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)-
hsdb 215
digitoxine [inn-french]
carditalin
mono-digitoxid [german]
monodigitoxoside
brn 0076678
digitrin
ccris 7116
nsc 7529
digitoxinum [inn-latin]
digicor
caswell no. 349
digitalis
digitossina [dcit]
epa pesticide chemical code 097002
asthenthilo
digitoxosidum
card-20(22)-enolide, 3-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxy, (3beta,5beta)-
digitalin, crystalline
digitoxinum
einecs 200-760-5
digitoksim
digipural
digitoxina [inn-spanish]
digitoxigenin-tridigitoxosid [german]
MEGXP0_001901
ACON1_000610
3beta-[2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide
CHEBI:28544 ,
digitoxoside
71-63-6
digitoxin
C06955
digitoxin, >=92% (hplc), powder
DB01396
digitoxin (jan/usp/inn)
D00297
crystodigin (tn)
SMP1_000096
NCGC00142623-02
NCGC00142623-03
SR-01000721879-2
A572A148-EC30-47D2-A32A-C9D8A93F8EFC
D0542
tradigal
CHEMBL254219
BRD-K63668566-001-01-7
3-[(3s,5r,8r,9s,10s,13r,14s,17r)-3-[(2r,4s,5s,6r)-5-[(2s,4s,5s,6r)-5-[(2s,4s,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahyd
LMST01120018
3beta-[2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide
card-20(22)-enolide, 3-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1.fwdarw.4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)-
mono-digitoxid
digitoxigenin-tridigitoxosid
digitossina
e90nzp2l9u ,
digitoxin [usp:inn:ban:jan]
unii-e90nzp2l9u
digitoxine
card-20(22)-enolide, 3-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)-
digitoxina
cas-71-63-6
tox21_302269
dtxsid0022933 ,
dtxcid102933
NCGC00255265-01
tox21_111659
WDJUZGPOPHTGOT-XUDUSOBPSA-N
digitaline
AKOS015915863
digitoxin [who-ip]
digitoxin [hsdb]
digitoxin [vandf]
digoxin impurity a [ep impurity]
digitoxin [who-dd]
digitoxin [usp-rs]
digitoxin [orange book]
digitoxin [usp impurity]
(3.beta.,5.beta.)-3-((o-2,6-dideoxy-.beta.-d-ribo-hexapyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide
digitoxin [mi]
3.beta.-((2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-14-hydroxy-5.beta.-card-20(22)-enolide
digitoxinum [who-ip latin]
digitoxin [jan]
digitoxin [ep monograph]
digitoxinum [hpus]
digitoxin [usp monograph]
card-20(22)-enolide, 3-((o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3.beta.,5.beta.)-
(3.beta.,5.beta.)-3-((o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide
digitoxin [inn]
4-[(3s,5r,8r,9s,10s,13r,14s,17r)-3-[(2r,4s,5s,6r)-5-[(2s,4s,5s,6r)-5-[(2s,4s,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahyd
gtpl6782
CCG-208538
3-[(3s,5r,8r,9s,10s,13r,14s,17r)-3-[(2r,4s,5s,6r)-5-[(2s,4s,5s,6r)-5-[(2s,4s,5s,6r)-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5
card-20(22)-enolide, 3-((o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)-
SCHEMBL20940
tox21_111659_1
NCGC00142623-04
cid_441207
bdbm46356
Q-100791
REGID_FOR_CID_441207
CS-5502
HY-B1357
digitoxin, usp
digitoxin, united states pharmacopeia (usp) reference standard
digitoxin, european pharmacopoeia (ep) reference standard
4-((1s,2s,5s,11s,7r,10r,14r,15r)-5-{5-[5-((2s,4s,5s,6r)-4,5-dihydroxy-6-methyl (2h-3,4,5,6-tetrahydropyran-2-yloxy))(4s,5s,2r,6r)-4-hydroxy-6-methyl(2h-3,4,5 ,6-tetrahydropyran-2-yloxy)](4s,5s,2r,6r)-4-hydroxy-6-methyl(2h-3,4,5,6-tetrah ydropyran-2-yloxy)
SBI-0051348.P003
NCGC00142623-05
4-((3s,5r,8r,9s,10s,13r,14s,17r)-3-(((2r,4s,5s,6r)-5-(((2s,4s,5s,6r)-5-(((2s,4s,5s,6r)-4,5-dihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-4-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-4-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-14-hydroxy-10,13-dim
digitoxin, british pharmacopoeia (bp) reference standard
Q423890
Z1552200029
1339-93-1
digitoxin 100 microg/ml in acetonitrile
NCGC00094652-06
D89676
EN300-123649
4-[(1r,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2r,4s,5s,6r)-5-{[(2s,4s,5s,6r)-5-{[(2s,4s,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-hexadecahydro-1h-cyclopenta[a]phena
AS-75726
digitoxin for lc assay
(3beta,5beta)-3-((o-2,6-dideoxy-beta-d-ribohexopyranosyl-(1-4)-o-2,6-dideoxy-bet a-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydro xycard-20(22)- enolide
(3beta,5beta)-3-((o-2,6-dideoxy-beta-d-ribo-hexapyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide
(3beta,5beta)-3-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide
digoxin impurity a (ep impurity)
card-20(22)-enolide, 3-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxy-,(3beta, 5beta)-
digitoxina (inn-spanish)
digitoxinum (inn-latin)
cp4071
(3beta,5beta)-3-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide
usepa/opp pesticide code: 097002
digitoxin (usp impurity)
digitoxin (usp monograph)
digitoxine (inn-french)
c01aa04
3beta-(2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyloxy)-14-hydroxy-5beta-card-20(22)-enolide
digitoxin (usp:inn:ban:jan)
3beta-(2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyloxy)-14-hydroxy-5beta,14beta-card-20(22)-enolide
digitoxin (usp-rs)
digitoxin (ep monograph)
3beta-((2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxy-5beta-card-20(22)-enolide

Research Excerpts

Overview

Digitoxin is a cardiotonic drug, which has been demonstrated to exhibit anticancer effects in a number of cancers. It is a known substrate of the efflux pump P-glycoprotein.

ExcerptReferenceRelevance
"Digitoxin is a cardiotonic drug, which has been demonstrated to exhibit anticancer effects in a number of cancers."( Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells.
Cao, X; Lin, Y; Ma, K; Mi, C; Wang, TY; Wei, M; Xu, W; Zhang, J, 2022
)
2.89
"Digitoxin is a cardiotonic drug, which has been demonstrated to exhibit anticancer effects in a number of cancers, but not in HCC."( Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
Chen, PC; Guo, L; Huang, Y; Kwok, HF; Li, B; Li, L; Lin, Y; Meng, C; Neves, H; Xiao, Y; Yan, W, 2017
)
2.62
"Digitoxin is a known substrate of the efflux pump P-glycoprotein (gene name: ABCB1). "( The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients.
Bachmakov, I; Bertsch, T; Diewald, C; Dragonas, C; Fromm, MF; Heppner, HJ; Muhlberg, W; Pahl, A; Sieber, CC; Wagner, JT; Wicklein, S, 2008
)
2.03

Effects

Digitoxin has been shown to have negative effects on cancer cell viability. The actual mechanism is still unknown. Anti-digitoxin antibodies have been produced by immunizing rabbits.

ExcerptReferenceRelevance
"Digitoxin has repeatedly shown to have negative effects on cancer cell viability; however, the actual mechanism is still unknown. "( Digitoxin Affects Metabolism, ROS Production and Proliferation in Pancreatic Cancer Cells Differently Depending on the Cell Phenotype.
Ejeskär, K; Lindholm, H; Szekeres, F, 2022
)
3.61
"Digitoxin also has effects on global gene expression in CF cells."( Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells.
Caohuy, H; Eidelman, O; Heldman, E; Huang, W; Jacobson, KA; Jozwik, C; Paweletz, C; Pollard, BS; Pollard, HB; Srivastava, M; Yang, Q; Zhang, J, 2004
)
2.49
"Anti-digitoxin antibodies have been produced by immunizing rabbits and by monoclonal techniques using the same digitoxin-protein conjugate. "( A comparative study between animals and monoclonal anti-digitoxin antibodies.
Collignon, A; Edelman, L; Scherrmann, JM, 1984
)
1.03

Treatment

Digitoxin treatment significantly decreased heart rate and diastolic blood pressure during the overnight sleeping phase of day 4 and day 10 compared with placebo (P < 0.05) The treatment elicited the appearance of a digoxin-like material in the progeny generations.

ExcerptReferenceRelevance
"Digitoxin treatment induced apoptosis in all four cell lines, but to different degrees."( Digitoxin Affects Metabolism, ROS Production and Proliferation in Pancreatic Cancer Cells Differently Depending on the Cell Phenotype.
Ejeskär, K; Lindholm, H; Szekeres, F, 2022
)
2.89
"Digitoxin treatment prevented an increase in rSNA (98 ± 14 pps, n = 7)."( Digitoxin improves cardiovascular autonomic control in rats with heart failure.
Antonio, EL; Campos, RR; da Veiga, GL; Fardin, NM; Montemor, JA; Tucci, PJ, 2016
)
2.6
"Digitoxin treatment showed a trend toward reduction in sputum free neutrophil elastase and neutrophil counts, but not a reduction in sputum IL-8."( Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
Boyle, MP; Callahan, KA; Diener-West, M; Lechtzin, N; Lee, S; Pollard, B; Talbot, CC; Zeitlin, PL, 2017
)
2.62
"Digitoxin treatment significantly decreased heart rate and diastolic blood pressure during the overnight sleeping phase of day 4 (HR, 8 beats min-1; DBP, 7 mmHg) and day 10 (HR, 7 beats min-1; DBP, 5 mmHg) compared with placebo (P < 0.05)."( Effects of digoxin and digitoxin on circadian blood pressure profile in healthy volunteers.
Grossmann, M; Jamieson, MJ; Kirch, W, 1998
)
1.33
"Digitoxin treatment elicited the appearance of a digoxin-like material in the progeny generations."( Induction of digoxin-like material production, and the digoxin binding in the unicellular organism Tetrahymena by digitoxin.
Csaba, G; Kovács, P; Müller, WE, 1998
)
1.23
"Digitoxin treatment delayed the onset, reduced the incidence, and ameliorated the magnitude of the hypertensive response in such animals; it also reduced the degree of cardiac hypertrophy and the severity of nephrosclerosis and completely prevented enlargement of the adrenals and kidneys and atrophy of the thymus."( Protective effect of digitoxin in adrenal-compression hypertension.
Ayachi, S; Hall, CE, 1976
)
1.3
"Digitoxin treatment prevents the hypertrophy and the accumulation of proteins to the myocardium."( Collagen metabolism of the rat heart during experimental cardiac hypertrophy and the effect of digitoxin treatment.
Lindy, S; Turto, H, 1976
)
1.2
"Digitoxin treatment did not alter peak flow velocity or flow acceleration, but did significantly increase isovolumic (dP/dt)P-1."( Effect of prophylactic digitalization on the development of myocardial hypertrophy.
Arcilla, RA; Cutilletta, AF; Rudnik, M; Straube, R, 1977
)
0.98
"2. Digitoxin treatment delayed the onset, reduced the incidence and ameliorated the magnitude of the hypertensive response in such rats; it also reduced the degree of cardiac hypertrophy, the severity of nephrosclerosis and completely prevented enlargement of the adrenals and kidneys or atrophy of the thymus."( Delayed onset and reduced severity of adrenal-compression hypertension in rats treated with digitoxin.
Ayachi, S; Hall, CE; Hall, O, 1976
)
0.99
"Digitoxin treatment induced slight but significant increase in wet ventricle weight and myocardial RNA content (mg/ventricle)."( Study of the factors influencing cardiac growth. II. Digitoxin treatment and isoproterenol-induced cardiac hypertrophy in the rat.
Nosztray, K; Szabó, J; Szegi, J; Takács, IE, 1985
)
1.24
"Digitoxin treatment induced a slight increase in wet ventricle weight and a significant elevation of myocardial RNA content (mg/ventricles) and concentration (mg/g)."( Study of the factors influencing cardiac growth. III. Digitoxin treatment and thyroxine-induced cardiac hypertrophy in the rat.
Nosztray, K; Szabó, J; Szegi, J; Takács, IE, 1986
)
1.24
"Treatment with digitoxin seems to be more relevant as a monotherapy with trichlormethiazide/amiloride."( Effectiveness of digitoxin versus trichlormethiazide/amiloride in congestive heart failure NYHA class II/III and sinus rhythm.
Huonker, M; Irmer, M; Keul, J; Schmidt-Trucksäss, A; Sorichter, S; Staiger, J, 1999
)
0.98
"Treatment with digitoxin increased the apparent number of (Na+,K+)-ATPase sites in heart, cerebral cortex, and kidney."( (Na+,K+)-ATPase and noradrenergic regulation: effects of cardiac glycoside treatment and noradrenergic manipulations.
Swann, AC, 1985
)
0.61

Toxicity

digitoxin was safe for adults with CF lung disease, but it did not achieve a significant decrease in sputum inflammatory markers. At higher digitoxin dose levels only propranolol was able to reduce significantly the ED50 and the LD50.

ExcerptReferenceRelevance
" In both male and female animals the LD50 was reduced by one half as compared to control animals."( Effect of phenobarbital pretreatment on digitoxin toxicity and biotransformation in guinea-pigs.
Carvalhas, ML; Figueira, MA, 1979
)
0.53
"Digitalis glycosides have a narrow margin between therapeutic and toxic levels."( Digitalis toxicity: mechanisms, diagnosis, and management.
Bhatia, SJ; Smith, TW, 1987
)
0.27
"Enhanced susceptibility to toxic arrhythmias by digitalis administration has been reported in clinical and experimental myocardial infarction."( Enhancement of triggered activity in ischemic Purkinje fibers by ouabain: a mechanism of increased susceptibility to digitalis toxicity in myocardial infarction.
El-Sherif, N; Gough, WB; Hariman, RJ; Zeiler, RH, 1985
)
0.27
" All animals developed toxic arrhythmias (atrioventricular block, ventricular premature contractions and/or ventricular tachycardia)."( Reversal of digoxin toxicity with specific antibodies.
Butler, VP; Schmidt, DH, 1971
)
0.25
" Only 3 patients complained of adverse effects from verapamil during the double-blind phase of the study."( Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis.
Baessler, C; Morganroth, J; Panidis, IP, 1983
)
0.27
" Adverse reactions rates up to 20% had been observed in hospitalized patients."( [Incidence of side effects in digitalis therapy].
Flasch, H, 1982
)
0.26
" Observed on four drug-induced behavior categories, it was found that both clonidine and propranolol attenuated the toxic effects of relatively low dose levels of digitoxin, while at higher digitoxin dose levels only propranolol was able to reduce significantly the ED50 and the LD50."( Effect of age, clonidine or propranolol on behavioral toxicity induced with digitoxin in mice.
Felleman, VH; Palfai, T, 1982
)
0.69
" The guinea pig is the most susceptible mammal known, with an LD50 in the range 1-2 micrograms TCDD/kg, whereas the hamster is the most resistant species with an LD50 greater than 3000 micrograms/kg."( Interspecies differences in cancer susceptibility and toxicity.
Hengstler, JG; Oesch, F; Steinberg, P; Van der Burg, B, 1999
)
0.3
" There were no adverse events associated with the therapies."( Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity.
Birkhahn, RH; Gaeta, TJ; Van Deusen, SK, 2003
)
0.32
" It has been shown that the mutant protein is toxic in cell culture and triggers an apoptotic cascade resulting in activation of caspase-3."( A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor.
Fischbeck, KH; Piccioni, F; Roman, BR; Taylor, JP, 2004
)
0.32
" The adverse effects of CGs have been attributed to excessive accumulation of intracellular Ca(2+) resulting from inhibition of Na(+)/K(+)-ATPase ion transport activity."( Arrhythmogenic adverse effects of cardiac glycosides are mediated by redox modification of ryanodine receptors.
Carnes, CA; Györke, S; Ho, HT; Stevens, SC; Terentyev, D; Terentyeva, R, 2011
)
0.37
"65-fold more toxic in each cell line, respectively."( Digitonin synergistically enhances the cytotoxicity of plant secondary metabolites in cancer cells.
Eid, SY; El-Readi, MZ; Wink, M, 2012
)
0.38
"These results suggest that the arrhythmogenic adverse effects of CGs on Ca(2+) handling involve PI3K- and PKC-mediated stimulation of NOX2 and subsequent NOX2-dependent ROS release from the mitochondria; mitochondria-derived ROS then activate CaMKII with consequent phosphorylation of RyR2 at Ser 2814."( Ryanodine receptor phosphorylation by oxidized CaMKII contributes to the cardiotoxic effects of cardiac glycosides.
Anderson, ME; Biesiadecki, BJ; Brundage, EA; Fedorov, VV; Györke, S; Ho, HT; Hund, TJ; Liu, B; Lou, Q; Sen, CK; Snyder, JS; Velez-Cortes, F; Wang, H; Wehrens, XH; Ziolo, MT, 2014
)
0.4
"MATERIAL AND METHOD Enquiries addressed to the Norwegian Poison Information Centre and reports of fatal adverse effects to the Regional Drug Information Centres (RELIS) regarding intake of digitalis were analysed."( [Drug safety associated with the change of digitalis drug in Norway].
Haga, C; Opdal, MS; Stenberg-Nilsen, H; Tuv, SS; Zahl, PH, 2016
)
0.43
"1 mg daily for 28 days, digitoxin was safe for adults with CF lung disease, but it did not achieve a significant decrease in sputum inflammatory markers."( Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
Boyle, MP; Callahan, KA; Diener-West, M; Lechtzin, N; Lee, S; Pollard, B; Talbot, CC; Zeitlin, PL, 2017
)
2.2
" NF-kB promotes inflammatory responses, mediates adverse cardiac remodeling and has a function correlation with calcium."( High doses of digoxin increase the myocardial nuclear factor-kB and CaV1.2 channels in healthy mice. A possible mechanism of digitalis toxicity.
Ashry, IEM; Farghaly, HSM; Hareedy, MS, 2018
)
0.48

Pharmacokinetics

Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0. did not significantly alter these responses relative to the concomitant double-blind administration of placebo)

ExcerptReferenceRelevance
"Digoxin dosage regimens for patients on chronic intermittent hemodialysis (CIH) were calculated from pharmacokinetic data of digoxin in these patients between the during hemodialyses."( Pharmacokinetic aspects of digoxin in patients with terminal renal failure. IV. Clinical implications of own observations with a recent review of literature.
Oe, PL; van der Vijgh, WJ, 1978
)
0.26
"Current pharmacologic texts recognize no significant pharmacodynamic differences between the various cardiac glycosides."( Pharmacodynamic distinctions between ouabain, digoxin and digitoxin.
Dale, EM; Dalton, RE; Havemann, DF; Holden, P; Kilgore, WM; Runge, TM; Stephens, JC, 1975
)
0.5
" did not significantly alter these responses relative to the concomitant double-blind administration of placebo, nor did it alter the pharmacokinetic characteristics of plasma digitoxin at steady state."( Captopril does not interact with the pharmacodynamics and pharmacokinetics of digitoxin in healthy man.
Belz, GG; Butzer, R; de Mey, C; Elich, D; Schroeter, V, 1992
)
0.7
"To study possible pharmacokinetic interactions between two compounds a single-dose or a multiple dose experimental design may be used."( The importance of prospective planning of pharmacokinetic trials. Considerations of studies on the phenytoin-digoxin-(P-D) and phenytoin-digitoxin-(P-DT) interaction.
Rameis, H, 1992
)
0.49
" Group-3A dogs had a shortened beta phase half-life (t1/2 (beta] and a decreased distribution volume."( Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs.
Akahori, F; Kobayashi, K; Miyashita, H; Miyazawa, Y; Sato, T; Suzuki, T, 1990
)
0.51
" On the other hand, the elimination half-life of antiarrhythmic agents that have a large volume of distribution and are highly cleared by the liver may be twice as long in patients with CHF compared with normal subjects."( Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
Echt, DS; Roden, DM; Woosley, RL, 1986
)
0.27
" Similarly, elimination half-life determined in 4 volunteers once in presence and once in absence of Q was prolonged by 34."( Effects of quinidine, verapamil and nifedipine on the pharmacokinetics and pharmacodynamics of digitoxin during steady state conditions.
Kuhlmann, J, 1987
)
0.49
" The peak concentration was significantly higher on day 28."( Pharmacokinetics and pharmacodynamics of muzolimine in chronic heart failure.
Bjørnstad, H; Mølstad, P; Storstein, L, 1985
)
0.27
" RIA was applied to the pharmacokinetic study of sheep digoxin-specific Fab fragments in one patient acutely intoxicated by digitoxin and treated with Digidot."( Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans.
Cano, NJ; Sabouraud, AE; Scherrmann, JM; Thanh-Barthet, CV; Urtizberea, M, 1993
)
0.49
"The possibility of a pharmacokinetic interaction between carvedilol and digitoxin (Study I) or phenprocoumon (Study II) has been evaluated in groups of 12 healthy volunteers."( Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon.
Brei, R; Caspary, S; Harder, S; Merz, PG, 1993
)
0.76
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic models of digitoxin and digoxin, containing a peripheral non-serum effect compartment, were used to analyze outcomes in a non-systematic literature review of five clinical studies, using the computed concentrations of digitoxin and digoxin in the effect compartment of these models in an analysis of their outcomes."( The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to regular sinus rhythm.
Jelliffe, RW, 2014
)
0.7
" Values for total clearance of compounds from plasma should be one of the most important pharmacokinetic parameters for predictions."( Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" The binding of digitoxin and cardioactive metabolites to serum proteins was studied using equilibrium dialysis (an in vitro chemical assay) alone and in combination with a modified 86Rb method."( Studies on digitalis. V. The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin.
Storstein, L, 1976
)
0.81
" Within the frames of synergoantagonism interplay, the drug combination produced on some of the reactions an effect which was similar to that exerted by one of the components."( [Characteristics of the effect of drug combinations on the development of immediate hypersensitivity].
Chetverikov, GN,
)
0.13
" These data suggest that when used in combination with a converting enzyme inhibitor, oral milrinone improves exercise capacity but is associated with a high incidence of adverse events that appear to be related to excessive vasodilation."( Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators.
Adams, KF; Berk, M; Brozena, SC; Colucci, WS; Cowley, AJ; Grabicki, JM; Kubo, SA; LeJemtel, T; Littler, WA; Sonnenblick, EH, 1993
)
0.29
" The HPLC-separation used a 10 x 2 mm LiChrospher RP-18 5 microm guard column in combination with a 125 x 2 mm main column of the same material and a gradient containing methanol, caesium ions and formic acid."( Determination of the cardiac glycosides digoxin and digitoxin by liquid chromatography combined with isotope-dilution mass spectrometry (LC-IDMS)--a candidate reference measurement procedure.
Kaiser, P; Kramer, U; Kress, M; Meissner, D; Reinauer, H; Wood, WG, 2003
)
0.57
" Selected cardiac glycosides were tested in combination with four clinically relevant cytotoxic drugs (5-fluorouracil, oxaliplatin, cisplatin, irinotecan)."( Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
Bohlin, L; Felth, J; Fryknäs, M; Gullbo, J; Lindskog, M; Rickardson, L; Rosén, J; Wickström, M, 2009
)
0.35

Bioavailability

The delayed time to peak after a single dose of digoxin or digitoxin during cytostatic drug therapy shows that rate of absorption of both glycosides is reduced. The apolar, fat soluble digitoxin is very well absorbed from the intestine, its onset of action is slow, binds to a high degree to albumin and undergoes enterohepatic recirculation.

ExcerptReferenceRelevance
" A kinetic model study on the transfer constants between various body compartments has indicated that rifampicin is rapidly absorbed from the intestine and that the absorption rate increases with time."( Clinical pharmacokinetics of rifampicin.
Acocella, G,
)
0.13
" After 10 min at pH 1, and 60 min at pH 2, digitoxin was hydrolyzed to such an extent that bioavailability should have been significantly reduced."( Quantitative studies on acid hydrolysis of digitoxin.
Funcke, C; Hausamen, TU; Peters, U; Staib, W, 1978
)
0.78
" This can be ascribed to a higher absorption rate of beta-methyldigoxin from the digestive tract."( Multiclinical open studies on the effect of beta-methyldigoxin on congestive heart failure with atrial fibrillation.
Ito, Y; Kimura, E; Seki, K, 1975
)
0.25
" The apolar, fat soluble digitoxin is very well absorbed from the intestine, its onset of action is slow, binds to a high degree to albumin and undergoes enterohepatic recirculation which accounts for a long elimination half time and stability of plasmatic levels."( [The past and the present of cardiac glycosides. III. Pharmacokinetics].
Synek, P, 1991
)
0.58
" In six volunteers the bioavailability of 16AG from two PAG tablet formulations (1."( On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations.
Haustein, KO, 1986
)
0.27
" The bioavailability of digoxin is appreciably less than that of digitoxin, averaging about two-thirds to three-fourths of the equivalent dose given intravenously in the case of currently available tablet formulations."( Pharmacokinetics, bioavailability and serum levels of cardiac glycosides.
Smith, TW, 1985
)
0.51
"The pharmacokinetics and bioavailability of digitoxin were examined in six normal human subjects using an assay that separates digitoxin from its metabolites."( Pharmacokinetics and bioavailability of digitoxin by a specific assay.
Fenster, PE; Graves, PE; MacFarland, RT; Marcus, FI; Perrier, D, 1984
)
0.8
" Daily renal glycoside excretion, as a further measure of bioavailability of digitoxin, was also unchanged by the antacid."( [Digitoxin blood picture and renal elimination in long-term therapy with aluminum-magnesium hydroxide gel].
Kuhlmann, J, 1984
)
1.41
" The delayed time to peak after a single dose of digoxin or digitoxin during cytostatic drug therapy shows that rate of absorption of both glycosides is reduced."( Inhibition of digoxin absorption but not of digitoxin during cytostatic drug therapy.
Kuhlmann, J, 1982
)
0.77
" Since the absorption rate is not clinically relevant in patients on long-term glycoside therapy, our results indicate that digitoxin is preferable to digoxin in such patients."( Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion.
Kuhlmann, J; Rietbrock, N; Wilke, J, 1982
)
0.72
" constant) bioavailability may contribute to a further decrease of the frequency of toxic side-effects in future."( [Effective concentration and dosage for cardiac glycosides].
Förster, W; Weiss, M, 1980
)
0.26
" The bioavailability and biotransformation of digoxin do not vary between healthy subjects and patients with renal insufficiency."( Digitalis therapy in renal failure with special regard to digitoxin.
Rietbrock, N; Vöhringer, HF, 1981
)
0.51
" Multiple factors influencing plasma concentration of digitalis including pharmacokinetics, bioavailability and drug interactions with glycosides were described."( [Disturbances of rhythm and atrio-ventricular conduction in digitalis overdose. Case reports].
Bakowski, D; Brzyźkiewicz, H; Janion, M, 2001
)
0.31
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Digitoxin is preferentially used in cases with suspected renal insufficiency. Alteration of digoxin and digitoxin dosage during repeated plasma exchanges is not recommended, but drugs should be given after, not before plasma exchange.

ExcerptRelevanceReference
" Dosage regimens based on the measurement of creatinine-clearance are of little help in "effective digitalisation"."( Digitalis pharmacokinetics and therapy with respect to impaired renal function.
Kramer, P, 1977
)
0.26
" The diagnosis was confirmed by chemical analysis of tissues and botanical examination of rumen contents, and a similar fatality was produced in a penned red deer by test dosing with powdered foxglove leaves."( Foxglove (Digitalis purpurea) poisoning in farmed red deer (Cervus elaphus).
Corrigall, W; Forbes, JC; Moody, RR, 1978
)
0.26
" Charts were compared with established criteria to determine whether the assay was indicated and performed correctly and whether dosage was adjusted correctly based on assay results."( Appropriateness of the use of serum digoxin and digitoxin assays.
Schneider, PJ; Slaughter, RL; Visconti, JA, 1978
)
0.51
"Digoxin dosage regimens for patients on chronic intermittent hemodialysis (CIH) were calculated from pharmacokinetic data of digoxin in these patients between the during hemodialyses."( Pharmacokinetic aspects of digoxin in patients with terminal renal failure. IV. Clinical implications of own observations with a recent review of literature.
Oe, PL; van der Vijgh, WJ, 1978
)
0.26
" The patients who were kept on their individually adjusted oral digitoxin maintenance dosage received the three preparations in a randomised order."( [Gycoside serum concentrations under maintenance therapy with Lanicor, Card-Lamuran, MF708d, and Lanitop (author's transl)].
Glocke, M; Olcay, A; Teufel, W; Weiss, W, 1975
)
0.49
" In that way of dose-response curves for the rapid effects of ouabain and other inhibitors of active Na transport were obtained with both the original, ouabain-sensitive (OS) and the variant, ouabain-resistant (OR) cells."( Variant HeLa cells selected for their resistance to ouabain.
Rosenberg, HM, 1975
)
0.25
" Walking exercise induced 1:1 conduction in six patients and was promoted by the following circumstances: 1) atrial rates of 250/min or less; 2) inadequate dosage of digitalis; and 3) the administration of quinidine."( The influence of exercise on atrial flutter.
Gooch, AS; Sumathisena, DR, 1975
)
0.25
" It permits early detection of digitalis intoxication in the absence of marked clinical and ECG evidence, and adjustment of dosage accordingly."( [Proceedings: Clinical value of serum digoxin and digitoxin determination in renal insufficiency].
Ferrini, B; Klauser, H; Klauser-Reucker, C; Moccetti, T, 1975
)
0.51
" It is demonstrated that an statistically significant pharmacokinetic interaction was found only after multiple dosing under conditions of steady-state, whereas after single dosing no interaction was observed."( The importance of prospective planning of pharmacokinetic trials. Considerations of studies on the phenytoin-digoxin-(P-D) and phenytoin-digitoxin-(P-DT) interaction.
Rameis, H, 1992
)
0.49
" The main problems in this case were regulation of the dosage and acquiring the necessary amount of antidote which greatly exceeded the hospital's own depot."( [Severe digitalis poisoning after the ingestion of 1 g of digoxin].
Bodmann, KF; Schuster, HP; Tröster, S, 1992
)
0.28
" All patients were treated with atenolol at dosage of 50 mg/die."( [Neurohumoral changes in patients with heart failure treated chronically with beta-blockers].
Mattioli, AV; Mattioli, G, 1991
)
0.28
" Similar dose-response curves for the inhibition of the enzyme activity were determined for both drugs."( Binding properties and biological effects of oxidized-ouabain on cultured neonatal-rat cardiac myocytes. Implications on the mechanism of action of the digitalis-glycosides.
Eilam, Y; Hallaq, H; Heller, M; Panet, R, 1991
)
0.28
" For these fractions dose-response curves for 86Rb uptake and for displacement of digoxin were parallel, respectively, to those of ouabain and digoxin, suggesting similarities of digoxin-like immunoreactive substance to cardiac glycosides."( Partial purification of endogenous digitalis-like compound(s) in cord blood.
Balzan, S; Biver, P; Gazzetti, P; Ghione, S; Montali, U, 1991
)
0.28
" The steady-state serum concentrations of digoxin and digitoxin can be affected if the changes in absorption are of sufficient magnitude, and adjustments in digoxin or digitoxin dosage may be required."( Current status of cardiac glycoside drug interactions.
Hooymans, PM; Merkus, FW,
)
0.38
" The physician's assumptions underdosage?, optimum dosage schedule? or overdosage? were confirmed by the laboratory results in 22."( [Therapeutic drug monitoring of digitoxin--results of 3 years' experience].
Haustein, KO; Winkler, U, 1989
)
0.56
"In 43 ICU patients undergoing continuous volume constant hemofiltration (CVHF), the pharmacokinetics of 12 drugs were investigated to ensure correct dosage adjustments."( [Dosage adjustment of drugs during continuous hemofiltration. Results and practical consequences of a prospective clinical study].
Dehne, M; el Abed, K; Hofmann, W; Kroh, U; Lennartz, H, 1989
)
0.28
"A randomized, crossover, single-blind study compared the efficacy and dosing accuracy of digoxin and digitoxin in 15 ambulatory patients wth congestive heart failure."( A comparative trial of digoxin and digitoxin in the treatment of congestive heart failure.
Bussey, HI; Gaspard, JJ; Hawkins, DW; Walsh, RA, 1988
)
0.77
" To determine whether quinidine affects digitoxin kinetics and cardiac efficacy, we measured glycoside plasma concentrations and renal excretion as well as ECG parameters and systolic time intervals before and during quinidine dosing in eight healthy subjects at steady state."( Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions.
Dohrmann, M; Kuhlmann, J; Marcin, S, 1986
)
0.78
"To determine whether verapamil, diltiazem, or nifedipine affect digitoxin kinetics, glycoside plasma concentrations and renal excretion were measured before and during steady-state dosing in 30 patients with cardiac insufficiency."( Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin.
Kuhlmann, J, 1985
)
0.73
" These preliminary data indicate a change in the pharmacokinetics of muzolimine on chronic dosing with more rapid absorption, higher peak concentrations, and increased area under the other plasma concentration curves."( Pharmacokinetics and pharmacodynamics of muzolimine in chronic heart failure.
Bjørnstad, H; Mølstad, P; Storstein, L, 1985
)
0.27
"Equations were derived to simulate the course of plasma drug concentration versus time curves for a multiple dosing regimen of drugs with a long biological half-life in those cases when Vrel and t1/2 or k in a particular subject do not correspond to the average values underlying the calculation of a standard dose."( A simple approach to estimate the variability of individual plasma drug concentrations in patients at a standardized multiple dosing regimen.
Barthel, W, 1985
)
0.27
" Thus, the influence of multiple plasma exchanges on the steady-state kinetics of digoxin and digitoxin will be limited and dosage adjustment is not required, if these drugs are given after - not before - the procedure and hypoalbuminaemia is corrected."( Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin.
Distler, A; Keller, F; Kreutz, G; Offermann, G; Vöhringer, HF,
)
0.58
" Alteration of digoxin and digitoxin dosage during repeated plasma exchanges is not recommended, but drugs should be given after, not before plasma exchange."( Effect of repeated plasma exchange on steady state kinetics of digoxin and digitoxin.
Hauff, A; Keller, F; Kreutz, G; Molzahn, M; Offermann, G; Reeck, S; Schultze, G; Vöhringer, F, 1984
)
0.79
" The appropriate dosage has to be adapted to the estimated lean body mass and, if necessary, reduced in a thin person, Digitoxin is preferentially used in cases with suspected renal insufficiency (especially in elderly patients)."( [Alternatives to glycoside therapy?].
Kubicek, F, 1983
)
0.47
" The dose-response curves for the positive inotropism can only be compared reliably once the equilibrium of drug action has been established."( Electrophysiological studies of some semisynthetic cardiac glycoside derivatives in isolated papillary muscle of the guinea-pig.
Lüllmann, H; Niehus, U; Pulss, W; Ravens, U, 1983
)
0.27
" Since more than half had signs of early renal function impairment, creatinine clearance should be taken into account when determining the dosage of a digoxin preparation especially in elderly patients; alternatively, digitoxin should be prescribed."( [Epidemiology of digitalis medication. Results of the Munich blood-pressure study].
Döring, A; Keil, U; Koenig, W; Mraz, W; Pöppl, SJ; Stieber, J, 1984
)
0.45
" New dosage guidelines have resulted from these studies."( [Which digitalis therapy is still justified today? (author's transl)].
Kümmell, HC, 1980
)
0.26
" Our results indicate the need for very exact monitoring of digoxin dosage during cytostatic therapy."( Inhibition of digoxin absorption but not of digitoxin during cytostatic drug therapy.
Kuhlmann, J, 1982
)
0.53
" On the basis of this assumption maintenance dosage regiments must be adjusted."( Digitalis therapy in renal failure with special regard to digitoxin.
Rietbrock, N; Vöhringer, HF, 1981
)
0.51
" Serum digitoxin concentrations were measured during the period of dosage and in the 21 day post-dosage washout."( Digitoxin accumulation.
Greenblatt, DJ; Hartlapp, J; Ochs, HR; Pabst, J, 1982
)
2.16
" about half the effective dosage initially considered."( [Digitoxin poisoning: reversing ventricular fibrillation with Fab fragments of anti-digoxin antibody].
Abuaf, N; Baud, F; Bismuth, C; Bolo, A; Domart, Y; Fournier, PE; Gailliot, M; Pontal, PG; Schermann, JM, 1982
)
1.17
" The recommended technique facilitates dosage calculations in patients treated with digitoxin."( Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment.
Haustein, KO, 1981
)
0.73
" At extremely long half-lives, relative to the period of dosing being monitored, sensitivity approaches 100% if measurement error is in the 1-2% range."( A computer model for the measurement of compliance using a dual tracer technique.
McDonald, J; Shine, D, 1997
)
0.3
" Thus, the dosage of digitoxin appears to be fully compensated during concomitant use of phenobarbital, but obviously deserves attention during concomitant use of phenytoin or carbamazepine."( [Serum digitoxin in concomitant use of antiepileptics in routine therapy].
Aass, H; Johannessen, SI; Osnes, JB; Skomedal, T; Stokke, KT, 1997
)
1.07
" An internal dose-response analysis revealed a relationship between high plasma concentration of digitoxin and a lower risk for leukemia/lymphoma and for cancer of the kidney/urinary tract."( Digitoxin medication and cancer; case control and internal dose-response studies.
Haux, J; Klepp, O; Spigset, O; Tretli, S, 2001
)
1.97
" The therapeutic and toxic dosage of digitalis is clinically affected by the variations in potassium concentrations."( The relation of potassium to digitalis effectiveness and toxicity.
SAMPSON, JJ, 1963
)
0.24
" Third, the dose-response characteristics of digitalis were well known to Withering."( William Withering's legacy--for the good of the patient.
Breckenridge, A,
)
0.13
"The impact of ABCB1 3435 CC, CT, and TT genotypes on SDC and SDC normalized for daily digitoxin dosage and body weight was assessed by multivariate regression analysis."( The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients.
Bachmakov, I; Bertsch, T; Diewald, C; Dragonas, C; Fromm, MF; Heppner, HJ; Muhlberg, W; Pahl, A; Sieber, CC; Wagner, JT; Wicklein, S, 2008
)
0.81
"We studied trends in dosing and serum concentrations of digitoxin in the period 2000 - 08, based on 13 054 serum samples sent to our laboratory for analysis in that period."( [Dosing of digitoxin in clinical practice].
Hønnås, A; Reimers, A; Spigset, O, 2010
)
1
" The selected compounds differed by the slopes of their dose-response curve: compounds with a slope of 1 (GCV) representing one target or noncooperativity and compounds with high slopes indicating positive cooperativity."( In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.
Arav-Boger, R; Cai, H; Forman, M; He, R; Kapoor, A; Posner, GH; Venkatadri, R, 2014
)
0.4
" Dosage regimens achieved ≤11 ng/g in the model's peripheral compartment."( The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to regular sinus rhythm.
Jelliffe, RW, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitorAn EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of Na(+)/K(+)-transporting ATPase (EC 3.6.3.9).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cardenolide glycosideAny member of the class of cardenolides with glycosyl residues attached to position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (64)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency3.98110.044717.8581100.0000AID485341
Chain A, CruzipainTrypanosoma cruziPotency3.98110.002014.677939.8107AID1476
acetylcholinesteraseHomo sapiens (human)Potency0.03470.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.15740.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency0.05710.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency0.14580.004110.890331.5287AID504467
SMAD family member 3Homo sapiens (human)Potency0.05710.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency0.27350.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency7.49780.000714.592883.7951AID1259369
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency0.34490.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588515; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency1.25890.00527.809829.0929AID588855
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency0.13190.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.16360.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency0.27270.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.55970.000214.376460.0339AID588533; AID720691; AID720692
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.10890.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.08040.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency0.24960.375827.485161.6524AID588526; AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency0.01950.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.67710.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
67.9K proteinVaccinia virusPotency3.58430.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.30920.001024.504861.6448AID588534; AID588535; AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency1.17950.001019.414170.9645AID588536; AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.63380.023723.228263.5986AID588541; AID743222; AID743223
IDH1Homo sapiens (human)Potency0.20600.005210.865235.4813AID686970
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.60530.001628.015177.1139AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency0.34380.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.048619.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.22850.057821.109761.2679AID1159526
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency14.12540.10009.191631.6228AID1346983
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency0.25120.01262.451825.0177AID485313
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.07080.010039.53711,122.0200AID588547
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.01640.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency22.69550.000323.4451159.6830AID743065; AID743067
ras-related protein Rab-9AHomo sapiens (human)Potency0.22390.00022.621531.4954AID485297
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.43790.000627.21521,122.0200AID651741; AID743202
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency1.58490.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency0.13550.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency1.12200.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.06830.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.02640.00339.158239.8107AID1347407
Cellular tumor antigen p53Homo sapiens (human)Potency0.02760.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.06830.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency1.91660.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.02560.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
STAT3, partialHomo sapiens (human)IC50 (µMol)0.70000.07604.07588.6430AID1399
signal transducer and activator of transcription 1-alpha/beta isoform alphaHomo sapiens (human)IC50 (µMol)55.70009.25409.25409.2540AID1411
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)20.50000.11007.190310.0000AID1449628; AID1473738
Sodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)IC50 (µMol)0.00800.00480.78076.0000AID56911
Sodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)IC50 (µMol)0.00800.00480.81346.0000AID56911
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)0.23000.00022.45859.9600AID1804171
Sodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)IC50 (µMol)0.00800.00480.81346.0000AID56911
Sodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)IC50 (µMol)0.00800.00480.81346.0000AID56911
Sodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)IC50 (µMol)0.00800.00480.81346.0000AID56911
Sodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)IC50 (µMol)0.00800.00800.35800.5000AID56912
Sodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)IC50 (µMol)0.00800.00480.81346.0000AID56911
Sodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)IC50 (µMol)0.00800.00480.81346.0000AID56911
Sodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)IC50 (µMol)0.00800.00480.81346.0000AID56911
Solute carrier organic anion transporter family member 4C1Homo sapiens (human)IC50 (µMol)0.12000.12002.87008.0000AID679785
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (303)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of the force of heart contractionSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
regulation of sodium ion transportSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
intracellular sodium ion homeostasisSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
osmosensory signaling pathwaySodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
regulation of blood pressureSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
response to xenobiotic stimulusSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
intracellular potassium ion homeostasisSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
negative regulation of glucocorticoid biosynthetic processSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
negative regulation of heart contractionSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
positive regulation of heart contractionSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
positive regulation of striated muscle contractionSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
relaxation of cardiac muscleSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
cellular response to steroid hormone stimulusSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
membrane repolarizationSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
proton transmembrane transportSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
response to glycosideSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
intracellular calcium ion homeostasisSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
intracellular sodium ion homeostasisSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
cell adhesionSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
regulation of gene expressionSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
intracellular potassium ion homeostasisSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
positive regulation of ATP-dependent activitySodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
sodium ion transmembrane transportSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
protein transport into plasma membrane raftSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
innate immune responseSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
ATP metabolic processSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
protein stabilizationSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
relaxation of cardiac muscleSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
cardiac muscle contractionSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
protein localization to plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
membrane repolarizationSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
monoatomic cation transmembrane transportSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
positive regulation of potassium ion transmembrane transporter activitySodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
proton transmembrane transportSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
positive regulation of sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
positive regulation of calcium:sodium antiporter activitySodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
positive regulation of potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
positive regulation of P-type sodium:potassium-exchanging transporter activitySodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
intracellular sodium ion homeostasisSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
intracellular potassium ion homeostasisSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
regulation of resting membrane potentialSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
cellular response to steroid hormone stimulusSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
response to glycosideSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
cellular response to amyloid-betaSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
neuron projection maintenanceSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
proton transmembrane transportSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
retina homeostasisSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
lateral ventricle developmentSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
third ventricle developmentSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
neuronal-glial interaction involved in hindbrain glial-mediated radial cell migrationSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
photoreceptor cell maintenanceSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
motor behaviorSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
plasma membrane bounded cell projection organizationSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
intracellular sodium ion homeostasisSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
positive regulation of neuron projection developmentSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
intracellular potassium ion homeostasisSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
cell-substrate adhesionSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
positive regulation of ATP-dependent activitySodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
protein stabilizationSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
membrane repolarizationSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
transport across blood-brain barrierSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
positive regulation of potassium ion transmembrane transporter activitySodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
positive regulation of sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
positive regulation of potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
negative regulation of glial cell migrationSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
behavioral fear responseSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of the force of heart contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of muscle contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
amygdala developmentSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
olfactory cortex developmentSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
locomotionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
negative regulation of heart contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
positive regulation of heart contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
negative regulation of cytosolic calcium ion concentrationSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
neurotransmitter uptakeSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
potassium ion transportSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
sodium ion transportSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
intracellular sodium ion homeostasisSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of smooth muscle contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of striated muscle contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of blood pressureSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
adult locomotory behaviorSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
visual learningSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
response to auditory stimulusSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
neuronal action potential propagationSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of vasoconstrictionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
L-ascorbic acid metabolic processSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
intracellular potassium ion homeostasisSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
response to nicotineSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
locomotory exploration behaviorSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
sodium ion transmembrane transportSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
response to potassium ionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
negative regulation of striated muscle contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
ATP metabolic processSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of glutamate uptake involved in transmission of nerve impulseSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of synaptic transmission, glutamatergicSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
relaxation of cardiac muscleSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
cardiac muscle contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
cellular response to mechanical stimulusSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
cellular response to steroid hormone stimulusSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
potassium ion transmembrane transportSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of cardiac muscle cell contractionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
membrane repolarizationSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
monoatomic cation transmembrane transportSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
transport across blood-brain barrierSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
negative regulation of calcium ion transmembrane transportSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
negative regulation of calcium:sodium antiporter activitySodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
response to glycosideSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
proton transmembrane transportSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
regulation of sodium ion transportSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
establishment or maintenance of transmembrane electrochemical gradientSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
intracellular sodium ion homeostasisSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
intracellular potassium ion homeostasisSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
positive regulation of ATP-dependent activitySodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
sodium ion transmembrane transportSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
protein stabilizationSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
potassium ion transmembrane transportSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
protein localization to plasma membraneSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
membrane repolarizationSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
positive regulation of potassium ion transmembrane transporter activitySodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
positive regulation of sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
positive regulation of potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
intracellular sodium ion homeostasisSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
intracellular potassium ion homeostasisSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
transmembrane transportSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
proton transmembrane transportSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
positive regulation of P-type sodium:potassium-exchanging transporter activitySodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
regulation of sodium ion transmembrane transporter activitySodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
monoatomic ion transportSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
potassium ion transportSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
sodium ion transportSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
cell surface receptor signaling pathwaySodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
spermatogenesisSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
fertilizationSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
flagellated sperm motilitySodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
regulation of cellular pHSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
sodium ion transmembrane transportSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
regulation of membrane potentialSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
establishment of localization in cellSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
potassium ion transmembrane transportSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
transport across blood-brain barrierSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
proton transmembrane transportSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
sodium ion export across plasma membraneSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
potassium ion import across plasma membraneSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
intracellular potassium ion homeostasisSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
intracellular sodium ion homeostasisSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
spermatogenesisSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
cell differentiationSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (93)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activitySodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
protein bindingSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
ATP bindingSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
phosphatase activitySodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
ATP hydrolysis activitySodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
potassium ion bindingSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
sodium ion bindingSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
transmembrane transporter bindingSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
protein heterodimerization activitySodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
protein-folding chaperone bindingSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
steroid hormone bindingSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
ATPase activator activitySodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activitySodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
protein bindingSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
protein kinase bindingSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
MHC class II protein complex bindingSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
protein-macromolecule adaptor activitySodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
protein heterodimerization activitySodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
ATPase bindingSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
amyloid-beta bindingSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activitySodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
protein bindingSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
ATP bindingSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
ATP hydrolysis activitySodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
metal ion bindingSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
protein-folding chaperone bindingSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
steroid hormone bindingSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
ATPase activator activitySodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
protein bindingSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
protein-macromolecule adaptor activitySodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
protein heterodimerization activitySodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
ATPase bindingSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activitySodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
steroid bindingSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
protein bindingSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
ATP bindingSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
phosphatase activitySodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
ATP hydrolysis activitySodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activitySodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
potassium ion bindingSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
sodium ion bindingSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
protein heterodimerization activitySodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
protein-folding chaperone bindingSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
steroid hormone bindingSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activitySodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
ATP bindingSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
ATP hydrolysis activitySodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
metal ion bindingSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
ATPase activator activitySodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
protein bindingSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
protein-macromolecule adaptor activitySodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
ATPase bindingSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
ATPase activator activitySodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
protein-macromolecule adaptor activitySodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
sodium channel regulator activitySodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
P-type sodium:potassium-exchanging transporter activitySodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
protein bindingSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
ATP bindingSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
ATP hydrolysis activitySodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activitySodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
kinase bindingSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
metal ion bindingSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 4C1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 4C1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (75)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
Golgi apparatusSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
sodium:potassium-exchanging ATPase complexSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
postsynaptic densitySodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
basolateral plasma membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
apical plasma membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
lateral plasma membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
T-tubuleSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
axonSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
organelle membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
sperm flagellumSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
sarcolemmaSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
melanosomeSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
membrane raftSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
photoreceptor inner segment membraneSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
extracellular exosomeSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
extracellular vesicleSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
protein-containing complexSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
sarcolemmaSodium/potassium-transporting ATPase subunit alpha-1 Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
sodium:potassium-exchanging ATPase complexSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
intercalated discSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
basolateral plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
apical plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
lateral plasma membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
T-tubuleSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
organelle membraneSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
sperm flagellumSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
sarcolemmaSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
extracellular exosomeSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
extracellular vesicleSodium/potassium-transporting ATPase subunit beta-1Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
photoreceptor inner segmentSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
endoplasmic reticulumSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
Golgi apparatusSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
membraneSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
axonSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
organelle membraneSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
neuronal cell body membraneSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
neuronal cell bodySodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
synapseSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
photoreceptor inner segment membraneSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
neuron to neuron synapseSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
extracellular vesicleSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
sodium:potassium-exchanging ATPase complexSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-3Homo sapiens (human)
photoreceptor inner segmentSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
cytoplasmSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
external side of plasma membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
apical plasma membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
lateral plasma membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
cell projection membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
cell body membraneSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
cell peripherySodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
astrocyte projectionSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
astrocyte end-footSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
neuron to neuron synapseSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
sodium:potassium-exchanging ATPase complexSodium/potassium-transporting ATPase subunit beta-2Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
endosomeSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
endoplasmic reticulumSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
caveolaSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
cell surfaceSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
intercalated discSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
membraneSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
T-tubuleSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
organelle membraneSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
cell projectionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
neuronal cell bodySodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
dendritic spineSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
extracellular vesicleSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
sodium:potassium-exchanging ATPase complexSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
cell projectionSodium/potassium-transporting ATPase subunit alpha-2Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
membraneSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
basolateral plasma membraneSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
axonSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
melanosomeSodium/potassium-transporting ATPase subunit alpha-1Canis lupus familiaris (dog)
plasma membraneSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
basolateral plasma membraneSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
apical plasma membraneSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
sperm flagellumSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
melanosomeSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
extracellular exosomeSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
sodium:potassium-exchanging ATPase complexSodium/potassium-transporting ATPase subunit beta-3Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
sodium:potassium-exchanging ATPase complexSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
extracellular exosomeSodium/potassium-transporting ATPase subunit gammaHomo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
membrane raftSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
sperm midpieceSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
photoreceptor cell ciliumSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
rod photoreceptor outer segmentSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
sodium:potassium-exchanging ATPase complexSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
plasma membraneSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
cell projectionSodium/potassium-transporting ATPase subunit alpha-4Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
azurophil granule membraneSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
specific granule membraneSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
extracellular exosomeSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (227)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID399017Induction of apoptosis in human TK10 cells assessed as necrotic cells at 3 nM for 48 hrs measured after 3 days of drug removal by fluorescence microscopy assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID553401Cytotoxicity against human NCI-H460 cells assessed as cell death at 50 nM after 12 hrs by Hoechst-33342 staining and propidium iodide staining2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
Stereochemical survey of digitoxin monosaccharides: new anticancer analogues with enhanced apoptotic activity and growth inhibitory effect on human non-small cell lung cancer cell.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1484220Antiproliferative activity against CD-1 mouse MOE cells harboring PTENshRNA/KRASG12V mutation after 72 hrs
AID1137820Effect on lovastatin-induced cell cycle arrest in HFF infected with HCMV assessed as accumulation at G0/1 phase treated for 24 hrs after incubation with early G1 inhibitor lovastatin for 48 hrs by propidium iodide staining based flow cytometry2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID399071Cytotoxicity against human SF268 cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409949Inhibition of human liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID471511Cytotoxicity against human CC20 cells after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID471516Cytotoxicity against human CC20 cells after 72 hrs by FMCA method relative to digoxin2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID91480Ability to bind to human serum albumin (HSA)1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Accumulation of drugs by guinea pig isolated atria. Quantitative correlations.
AID80738The dose producing 75% increase in contractility in guinea pig atria1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Cardenolide analogues. 14. Synthesis and biological activity of glucosides of C17 beta-modified derivatives of digitoxigenin.
AID1137814Cytotoxicity against HFF assessed as inhibition of cell viability after 3 days by MTT assay2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID1484230Induction of apoptosis in human OVSAHO cells assessed as upregulation of cleaved PARP expression at 100 nM after 72 hrs by Western blot analysis
AID1137816Cell cycle arrest in HFF infected with HCMV assessed as accumulation at G0/1 phase after 24 hrs by propidium iodide staining based flow cytometry2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID127479Binding affinity against murine monoclonal antibody (mAb)-40-502002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID593490Antiproliferative activity against human MCF7 cells assessed as cell viability treated for 48 hrs followed by compound washout measured after 72 hrs by fluorometric CellTiter-Blue reagent assay2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and evaluation of cardiac glycoside mimics as potential anticancer drugs.
AID553404Growth inhibition of human NCI-H460 cells after 48 hrs by MTT assay2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
Stereochemical survey of digitoxin monosaccharides: new anticancer analogues with enhanced apoptotic activity and growth inhibitory effect on human non-small cell lung cancer cell.
AID399073Cytotoxicity against human NCI-H460 cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID399067Cytotoxicity against human DU145 cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID1484216Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID399020Inhibition of topoisomerase 2alpha-mediated cleavage of double-stranded pRYG DNA assessed as linear DNA at 100 uM by agarose gel electrophoresis2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID78477Ability to bind to guinea pig atrial homogenate1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Accumulation of drugs by guinea pig isolated atria. Quantitative correlations.
AID1484212Inhibition of sodium potassium ATPase in human OVCAR3 cells assessed as upregulation of p21 protein expression at 100 nM by Western blot analysis
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1654447Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
AID471512Cytotoxicity against human HCT116 cells after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID399019Inhibition of topoisomerase 2alpha-mediated cleavage of double-stranded pRYG DNA assessed as linear DNA at 100 nM by agarose gel electrophoresis2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID227925The compound was estimated for biosensor analysis2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1484231Inhibition of sodium potassium ATPase in human OVCAR3 cells assessed as downregulation of p53 protein expression at 100 nM after 72 hrs by Western blot analysis
AID1484211Antiproliferative activity against CD-1 mouse MOE cells derived from 85 to 120 passages after 72 hrs
AID399068Cytotoxicity against human MCF7 cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID357577Binding affinity to mouse Monoclonal antibody DIG 64.2B.5 by ELISA relative to digoxin
AID1484234Inhibition of sodium potassium ATPase in human OVCAR3 cells assessed as reduction in TNFalpha-induced NFkappaB activation at 100 nM after 4 hrs by luciferase reporter gene assay relative to control
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID471509Cytotoxicity against human HCT116 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID471520Inhibition of TNF-alpha-stimulated NF-kappaB translocation from cytoplasm to nucleus in human MCF7 cells at 0.4 to 10 uM2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID1484205Antiproliferative activity against human OVCAR4 cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID471517Inhibition of Na+/K+ ATPase relative to digoxin2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1145690Inhibition of rat brain sodium/potassium-transporting ATPase in presence of Mg2+ and Na+1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Cardenolide analogues. 2. 22-Methylenecard-14-enolides.
AID1137819Effect on mimosine-induced cell cycle arrest in HFF infected with HCMV assessed as accumulation at G0/1 phase treated for 1 day after incubation with mid-G1 inhibitor mimosine for 48 hrs by propidium iodide staining based flow cytometry2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID1484225Cell cycle arrest in human OVCAR3 cells assessed as accumulation at G2/M phase at 100 nM after 72 hrs by propidium iodide staining-based flow cytometry method
AID399016Induction of apoptosis in human TK10 cells assessed as apoptotic cells at 3 nM for 48 hrs measured after 3 days of drug removal by fluorescence microscopy assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID1137810Antiviral activity against Human cytomegalovirus Towne infected in HFF assessed as decrease in virus DNA yield at 50 nM measured 96 hrs post-infection by real-time PCR analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID33556The ability concentration.)2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
AID1557489Toxicity in po dosed mouse2019Journal of natural products, 03-22, Volume: 82, Issue:3
Potential Anticancer Agents Characterized from Selected Tropical Plants.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID399015Induction of apoptosis in human TK10 cells assessed as viable cells at 3 nM for 48 hrs measured after 3 days of drug removal by fluorescence microscopy assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID56912Inhibition of [3H]ouabain binding to Digitalis receptor in dog heart microsomes1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis and structure-activity relationships of 17beta-substituted 14beta-hydroxysteroid 3-(alpha-L-rhamnopyranoside)s: steroids that bind to the digitalis receptor.
AID1484217Antiproliferative activity against human OVCAR3 cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID1484206Antiproliferative activity against human OVCAR5 cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID1484208Antiproliferative activity against human IOSE-80 cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID471514Cytotoxicity against human HT-29 cells after 72 hrs by FMCA method relative to digoxin2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID127349Binding affinity against human monoclonal antibody (mAb)-11E62002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID679785TP_TRANSPORTER: inhibition of Digoxin uptake in OATP4C1-expressing MDCK cells2004Proceedings of the National Academy of Sciences of the United States of America, Mar-09, Volume: 101, Issue:10
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.
AID1503774Cytotoxicity against human HL cells assessed as cell viability at 50 uM after 72 hrs by resazurin dye based fluorescence assay relative to control2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID1654445Cytotoxicity against human HT-29 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
AID1137818Cytotoxicity against HFF assessed as inhibition of cell proliferation at 0.1 uM after 3 days by MTT assay2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID399024Inhibition of topoisomerase 2beta in human K562 cells assessed as cleavage of supercoiled pRYG DNA at 300 nM after 24 hrs by TARDIS assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1484227Induction of apoptosis in human OVCAR3 cells assessed as upregulation of cleaved PARP expression at 100 nM by Western blot analysis
AID1484233Inhibition of sodium potassium ATPase in human OVCAR3 cells assessed as increase in ERK phosphorylation levels at 100 nM after 120 mins by Western blot analysis
AID1484232Inhibition of sodium potassium ATPase in human OVSAHO cells assessed as increase in ERK phosphorylation levels at 100 nM after 120 mins by Western blot analysis
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1484229Induction of apoptosis in human OVCAR3 cells assessed as decrease in Bcl-xL levels at 100 nM by Western blot analysis
AID680444TP_TRANSPORTER: inhibition of Ouabain uptake (Ouabain: 100 uM, Digitoxin: 100 uM) in Xenopus laevis oocytes1996The Journal of pharmacology and experimental therapeutics, Mar, Volume: 276, Issue:3
Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver.
AID1651447Inhibition of Sodium/potassium-transporting ATPase in porcine cerebral cortex using ATP as substrate incubated for 15 mins by ADP-Glo Max Assay
AID1484238Inhibition of sodium potassium ATPase in human OVCA432 cells assessed as downregulation of p53 protein expression at 100 nM after 72 hrs by Western blot analysis
AID399011Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1484210Antiproliferative activity against CD-1 mouse MOE cells derived from 8 to 25 passages after 72 hrs
AID399069Cytotoxicity against human HCT116 cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID471518Cytotoxicity against human colon cancer cells after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID471508Cytotoxicity against human CC20 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID127356Binding affinity against Monoclonal antibody mAB-1B3 using [3H]digoxin as radioligand2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID399022Inhibition of topoisomerase 2beta in human K562 cells assessed as cleavage of supercoiled pRYG DNA at 300 nM after 0.5 hrs by TARDIS assay relative to control2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID1484209Antiproliferative activity against human OVCAR8 cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID399070Cytotoxicity against human Hep3B cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID1484219Antiproliferative activity against CD-1 mouse MOE cells harboring scrambled RNA after 72 hrs
AID23672Partition coefficient (logP)1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Accumulation of drugs by guinea pig isolated atria. Quantitative correlations.
AID593489Binding affinity to pig kidney Na+/K+-ATPase assessed as inorganic phosphate release after 2 hrs2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and evaluation of cardiac glycoside mimics as potential anticancer drugs.
AID358946Induction of elastase release in human PMNC assessed as increase in p-nitroanilide formation2002Journal of natural products, Jan, Volume: 65, Issue:1
A neutrophil multitarget functional bioassay to detect anti-inflammatory natural products.
AID1484214Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID1484228Induction of apoptosis in human OVCAR3 cells assessed as decrease in Mcl-1 levels at 100 nM by Western blot analysis
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1137815Cytotoxicity against HFF assessed as inhibition of cell viability after 3 days by trypan blue exclusion assay2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID1484213Inhibition of sodium potassium ATPase in human OVSAHO cells assessed as upregulation of p21 protein expression at 100 nM by Western blot analysis
AID471521Inhibition of TNF-alpha-stimulated NF-kappaB translocation from cytoplasm to nucleus in human HeLa cells at 0.4 to 10 uM2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID24290The time required for offset of inotropy after addition of a single dose of delta F751982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Cardenolide analogues. 14. Synthesis and biological activity of glucosides of C17 beta-modified derivatives of digitoxigenin.
AID399021Inhibition of topoisomerase 2beta in human K562 cells assessed as cleavage of supercoiled pRYG DNA at 300 nM by TARDIS assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID1654448Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
AID1484207Antiproliferative activity against human Kuramochi cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID471510Cytotoxicity against human HT-29 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID471519Inhibition of TNF-alpha-stimulated NF-kappaB translocation from cytoplasm to nucleus in human HT-29 cells at 0.4 to 10 uM2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID399010Cytotoxicity against human TK10 cells after 48 hrs by SRB assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID56911Inhibition of [3H]- ouabain binding to digitalis receptor1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
Synthesis of 20-hydroxy-, 20-amino-, and 20-nitro-14-hydroxy-21-nor-5 beta,14 beta-pregnane C-3 glycosides and related derivatives: structure-activity relationships of pregnanes that bind to the digitalis receptor.
AID679458TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells2001Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 363, Issue:3
P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin.
AID399013Plasma concentration in human2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID399075Cytotoxicity against human NCI/ADR-RES cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID1484218Antiproliferative activity against human OVSAHO cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID399074Cytotoxicity against human A549 cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID1145691Inhibition of rat brain sodium/potassium-transporting ATPase after 10 mins in presence of Mg2+ and Na+1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Cardenolide analogues. 2. 22-Methylenecard-14-enolides.
AID399072Cytotoxicity against human SKOV3 cells after 72 hrs by calcein AM assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID1654446Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID127355Binding affinity against Monoclonal antibody mAB-1B3 using [3H]digitoxin as radioligand2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID471515Cytotoxicity against human HCT116 cells after 72 hrs by FMCA method relative to digoxin2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID409945Inhibition of human recombinant MAOA at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID399012Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID127352Binding affinity against human monoclonal antibody (mAb)-7F22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID1137813Antiviral activity against Human cytomegalovirus Towne infected in HFF assessed as inhibition of viral replication by measuring pp28 expression at 72 hrs post-infection by luciferase assay2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1484226Induction of apoptosis in human OVCAR3 cells assessed as upregulation of cleaved caspase 3 expression at 100 nM by Western blot analysis
AID1484203Inhibition of sodium potassium ATPase in human OVSAHO cells assessed as downregulation of p53 protein expression at 100 nM after 72 hrs by Western blot analysis
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1484215Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 aqueous one solution assay
AID1137811Antiviral activity against Human cytomegalovirus TB40 infected in HFF assessed as inhibition of viral replication at 50 nM after 3 days by GFP-based fluorescence analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1137817Selectivity index, ratio of CC50 for HFF to EC50 for Human cytomegalovirus Towne infected in human foreskin fibroblasts2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID24291The time required for onset of inotropy after addition of a single dose of delta F751982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Cardenolide analogues. 14. Synthesis and biological activity of glucosides of C17 beta-modified derivatives of digitoxigenin.
AID1137812Antiviral activity against Human cytomegalovirus Towne infected in HFF assessed as plaque reduction at 50 nM measured 8 days post-infection2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID399018Inhibition of topoisomerase 2alpha-mediated cleavage of double-stranded pRYG DNA assessed as linear DNA at 30 nM by agarose gel electrophoresis2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID127353Kinetic parameter against Monoclonal antibody mAB-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID1137809Antiviral activity against Human cytomegalovirus Towne infected in HFF assessed as inhibition of viral replication by measuring pp28 expression at 50 nM at 72 hrs post-infection by luciferase assay2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Digitoxin analogues with improved anticytomegalovirus activity.
AID127351Binding affinity against human monoclonal antibody (mAb)-5C22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1478416Toxicity in orally dosed mouse2017Journal of natural products, 03-24, Volume: 80, Issue:3
Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity.
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID399014Cytotoxicity against human K562 cells by XTT assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID471513Cytotoxicity against human HT-29 cells after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,924)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904181 (84.91)18.7374
1990's283 (5.75)18.2507
2000's219 (4.45)29.6817
2010's187 (3.80)24.3611
2020's54 (1.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.79 (24.57)
Research Supply Index8.58 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index118.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials90 (1.71%)5.53%
Reviews304 (5.78%)6.00%
Case Studies223 (4.24%)4.05%
Observational3 (0.06%)0.25%
Other4,639 (88.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Digitoxin to Treat Cystic Fibrosis [NCT00782288]Phase 224 participants (Actual)Interventional2010-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00782288 (13) [back to overview]Change in Il-8 (Interleukin 8) Levels From Day 28 Minus Day 1 (Treatment Period).
NCT00782288 (13) [back to overview]Change in Neutrophil Cell Count Day 28 Minus Day 1 (Treatment Period).
NCT00782288 (13) [back to overview]Change in WBC (White Blood Cell) Count by Group During Treatment Period
NCT00782288 (13) [back to overview]Changes in C Reactive Protein (CRP) During Treatment.
NCT00782288 (13) [back to overview]Changes in Erythrocyte Sedimentation Rate (ESR) During Treatment Period.
NCT00782288 (13) [back to overview]Clinically Significant Alterations in ECG Readings
NCT00782288 (13) [back to overview]Clinically Significant Changes in the Microbiology of Sputum in Subjects
NCT00782288 (13) [back to overview]Number of CF Subjects With Microarray Results From Nasal Epithelial Cells to Measure the Effect of Digitoxin on Gene Expression.
NCT00782288 (13) [back to overview]Safety Indices Including Change in FEV1 in Stable CF Patients.
NCT00782288 (13) [back to overview]Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.
NCT00782288 (13) [back to overview]Effect of Digitoxin on Neutrophil Counts in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.
NCT00782288 (13) [back to overview]Mean Change in Quality of Life Scores, for Each Domain, From Day 1 to Day 42 Using the Cystic Fibrosis Questionnaire Revised (CFQ-R).
NCT00782288 (13) [back to overview]Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients.

Change in Il-8 (Interleukin 8) Levels From Day 28 Minus Day 1 (Treatment Period).

Change in Il-8 values are expressed as a change in log 10 Il-8 pg/mL from Day 28 minus Day 1. (NCT00782288)
Timeframe: 28 days (Day 28 minus Day 1)

Interventionlog10 (pg/mL) (Median)
Placebo0.13
Low Dose 0.05mg Digitoxin-0.13
Higher Dose 0.1mg Digitoxin0.04

[back to top]

Change in Neutrophil Cell Count Day 28 Minus Day 1 (Treatment Period).

The change in log 10 neutrophil cell count from Day 28 minus Day 1 (during the treatment period) expressed as log (10^4 neutrophil/mL). (NCT00782288)
Timeframe: 28 days (Day 28 minus Day 1)

Interventionlog 10 (neutrophil cell/mL) (Median)
Placebo0.19
Low Dose 0.05mg Digitoxin-0.26
Higher Dose 0.1mg Digitoxin-0.02

[back to top]

Change in WBC (White Blood Cell) Count by Group During Treatment Period

Safety indices included changes in FEV1 (lung function), changes in WBC, alterations in ECG and sputum microbiology. There were no significant alterations in the ECG in any subjects over the course of the study. There were no subjects who acquired multiple resistant changes in microbiology of sputum and no acquisition of B. cepacia in any subjects. Therefore, these data were not analyzed. The median changes in FEV1 and median changes in WBC, ESR and CRP are reported. (NCT00782288)
Timeframe: Baseline and Day 28

InterventionK/cu mm (Median)
Placebo-510.28
Low Dose 0.05mg Digitoxin-0.98
Higher Dose 0.1mg Digitoxin-0.13

[back to top]

Changes in C Reactive Protein (CRP) During Treatment.

Median changes in CRP and IQR were assessed from serum samples collected at Visits 1,3, 4 and 5. (NCT00782288)
Timeframe: Baseline and Day 28

Interventionmg/dL (Median)
Placebo-0.20
Low Dose 0.05mg Digitoxin0.05
Higher Dose 0.1mg Digitoxin-0.05

[back to top]

Changes in Erythrocyte Sedimentation Rate (ESR) During Treatment Period.

Median change in serum ESR (mm/hr) and IQR was calculated from Treatment Period (28 days). (NCT00782288)
Timeframe: Baseline and Day 28

Interventionmm/hr (Median)
Placebo-1.00
Low Dose 0.05mg Digitoxin3.50
Higher Dose 0.1mg Digitoxin0.00

[back to top]

Clinically Significant Alterations in ECG Readings

Safety indices included an assessment for the number of clinically significant alterations in the subjects ECG readings from Day 1 to Day 28. (NCT00782288)
Timeframe: 28 days

Interventionparticipants (Number)
Placebo0
Low Dose 0.05mg Digitoxin0
Higher Dose 0.1mg Digitoxin0

[back to top]

Clinically Significant Changes in the Microbiology of Sputum in Subjects

Count of clinically significant changes in sputum microbiology during the Treatment phase (Day 1 to Day 28) to include any new acquisition of B. cepacia or new acquisition of any multiple resistant organism. (NCT00782288)
Timeframe: 28 days

Interventionparticipants (Number)
Placebo0
Low Dose 0.05mg Digitoxin0
Higher Dose 0.1mg Digitoxin0

[back to top]

Number of CF Subjects With Microarray Results From Nasal Epithelial Cells to Measure the Effect of Digitoxin on Gene Expression.

Rhinoprobe was used to collect nasal epithelial cells. The cells were collected pre and post-treatment and placed in Trizol for RNA isolation then used to measure the effect of digitoxin on gene expression. The full set of microarray data has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). The accession number for that data is GSE76347 (data available Dec 2018). (NCT00782288)
Timeframe: Day 0 and Day 28

Interventionparticipants (Number)
All Participants23

[back to top]

Safety Indices Including Change in FEV1 in Stable CF Patients.

Safety indices included changes in FEV1 (forced expiratory volume in 1 second), changes in WBC (white blood cell count), alterations in ECG and sputum microbiology. The median changes in FEV1 are reported. (NCT00782288)
Timeframe: Baseline and Day 28

Interventionliters (Median)
Placebo-0.00
Low Dose 0.05mg Digitoxin0.10
Higher Dose 0.1mg Digitoxin-0.02

[back to top]

Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.

The Il-8 measurements of sputum digitoxin levels for each group is shown for 5 days (Days 1, 14, 21, 28 and 42). (NCT00782288)
Timeframe: 42 days (Day 1 to Day 42)

,,
Interventionlog 10 (pg/mL) (Median)
IL-8 Day 1IL-8 Day 14IL-8 Day 21IL-8 Day 28IL-8 Day 42
Higher Dose 0.1mg Digitoxin5.045.015.175.204.97
Low Dose 0.05 mg Digitoxin4.964.894.774.794.74
Placebo4.594.945.084.664.59

[back to top]

Effect of Digitoxin on Neutrophil Counts in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.

The neutrophil counts were measured in the induced sputum of participants in each group on study 5 days (Days 1, 14, 21, 28 and 42). (NCT00782288)
Timeframe: 42 days (Day 1- Day 42)

,,
Interventionlog 10 (neutrophil cells/mL) (Median)
Day 1Day 14Day 21Day 28Day 42
Higher Dose 0.1mg Digitoxin2.932.712.882.772.82
Low Dose 0.05 mg Digitoxin2.822.262.232.162.06
Placebo2.582.892.862.712.55

[back to top]

Mean Change in Quality of Life Scores, for Each Domain, From Day 1 to Day 42 Using the Cystic Fibrosis Questionnaire Revised (CFQ-R).

"CFQ-R is a disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms. Developed specifically for use in patients with a diagnosis of cystic fibrosis. There are 9 Quality of life domains: physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions and 3 symptom scales: weight, respiratory, and digestion.~Scaling of items is done via 5 distinct 4-point Likert scales. Scores for each domain; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health. Based on clinician judgment of global clinical change, a moderate change was a standardized effect size of 0.50 units and an important change was a standardized effect size of 0.80 units evaluating pre- and post-treatment for CF exacerbation. Mean changes in CFQ-R Scores by Group were evaluated between Visit 6 and Visit 1, by Domain." (NCT00782288)
Timeframe: Baseline and Day 42

,,
Interventionmean change of scores on a scale (Mean)
Physical DomainRole DomainVitality DomainEmotional DomainSocial DomainBody DomainEating DomainTreatment DomainHealth DomainWeight DomainRespiratory DomainDigestion Domain
Higher Dose 0.1mg Digitoxin-2.601.041.044.17-4.178.33-1.395.56-4.17-0.00-6.94-5.56
Low Dose 0.05mg Digitoxin-14.58-1.044.17-5.00-5.56-4.17-1.396.944.1712.502.784.17
Placebo-5.210.00-2.08-5.83-2.086.94-1.391.391.390.00-2.78-9.72

[back to top]

Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients.

Digitoxin serum levels were drawn on Days 1 (pre-dose), 7, 14, 21 and 42. The range of digitoxin levels for each visit is listed and the number of subjects who had that level are marked by group (placebo, low dose and high dose). (NCT00782288)
Timeframe: Serum PK on Days 1 (pre-dose), 7, 14, 21 and 42

,,
Interventionparticipants (Number)
Day 7, digitoxin level 5.6 ng/mLDay 7, digitoxin level 6 ng/mLDay 7, digitoxin level 6.4 ng/mLDay 7, digitoxin level 6.9 ng/mLDay 7, digitoxin level 7.8 ng/mLDay 7, digitoxin level none detectedDay 14, digitoxin level 10 ng/mLDay 14, digitoxin level 11 ng/mLDay 14, digitoxin level 13 ng/mLDay 14, digitoxin level 6.8 ng/mLDay 14, digitoxin level 6.9 ng/mLDay 14, digitoxin level 7.3 ng/mLDay 14, digitoxin level 7.5 ng/mLDay 14, digitoxin level 8.1 ng/mLDay 14, digitoxin level 9.3 ng/mLDay 14, digitoxin level 9.4 ng/mLDay 14, digitoxin level none detectedDay 21, digitoxin level 10 ng/mLDay 21, digitoxin level 11 ng/mLDay 21, digitoxin level 12 ng/mLDay 21, digitoxin level 13 ng/mLDay 21, digitoxin level 14 ng/mLDay 21, digitoxin level 15 ng/mLDay 21, digitoxin level 4 ng/mLDay 21, digitoxin level 5 ng/mLDay 21, digitoxin level 6 ng/mLDay 21, digitoxin level 6.4 ng/mLDay 21, digitoxin level 6.5 ng/mLDay 21, digitoxin level 6.9 ng/mLDay 21, digitoxin level 7.5 ng/mLDay 21, digitoxin level none detectedDay 42, digitoxin level 5 ng/mLDay 42, digitoxin level none detected
Higher Dose 0.1mg Digitoxin111113101100111111111100000111008
Low Dose 0.05mg Digitoxin010007010011000050000011111000317
Placebo000008000000000080000000000000808

[back to top]